Novo is not alone in investing in combination approaches: in AstraZenecas 2023 announcement of its acquisition of Eccogenes GLP-1 program, the manufacturer noted that they intend to combine the GLP-1 asset with other products in their portfolio (e.g., Farxiga, baxdrostat) in an effort to address obesity comorbidities (e.g., heart disease, kidney disease, metabolic syndrome)
Research-market peptides are not manufactured to pharmaceutical identity and purity standards, so a vials contents cannot be assumed from its label without independent testing
GLP-1/GIP + B12 GLP-1/GIP + B12 combines dual GLP-1/GIP support with Vitamin B12 to support metabolic health, appetite awareness, energy production, and overall wellness as part of a structured lifestyle routine
Because coverage depends on your plan and diagnosis code, we review your options and provide transparent pricing, including labs and follow-up, before you start
94 ZhaoX.WangM.WenZ.LuZ.CuiL.FuC.et al (2021)
Ribas V et al